Fortress Investment Group: Bad Actor, Bad Timing, or Both?
Fortress Investment Group, a patent aggregator/investment firm, owns patents allegedly infringed by bioMérieux SA (among others) over the previous six years. In a lawsuit filed on March 9, 2020, Fortress, though its wholly-owned entity Labrador Diagnostics, is claiming bioMériux’s testing process is infringing U.S. Patents.
New Injunction Policy Boosts Power Of Essential Patents
In mid-December 2019, a policy statement was issued by the USPTO, NIST, and DOJ to clearly state injunctive relief (among other remedies) is available to holders of standard-essential patents (SEPs.)
China Seeks Patent on US COVID-19 Drug
Gilead's vaccine against the Ebola virus, Remdesivir, is proving effective in combating COVID-19, according to news reports and clinical trials.
Wells Fargo Was Ordered To Pay USAA $200 Million But They Might Only Be The First Of Many
This fall, a jury ordered Wells Fargo to pay USAA $200 million for infringing on patents relating to mobile image capture technology. Judging by even more recent "Wells Fargo must pay a fine" news, their patent issues may be the least of their concerns, but it will not likely be the end of the story here.
A New Plaintiff on the Patent Front: The U.S. Government vs. Gilead
President Trump has a reputation for unorthodox approaches. His administration's foray into patent enforcement is no exception.
AI and the Next Frontier in Healthcare and Patent Law
From diagnostics to robotic surgery to predictive analytics, AI is revolutionizing health care.
Software Patents – “That’s Where All The Action Is”
After graduating from engineering school, I remember speaking to my grandfather, who had worked as a chemical engineer for GE for his entire career after WWII.
Should You Pass on a Patent?
Sometimes a patent does not make business sense. It’s a conversation I have frequently with potential and existing clients, and after a brief discussion, drawing attention to important issues they should consider, they often arrive at the conclusion that it’s not worth it.